KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients

Margaret Bia, Deborah B. Adey, Roy D. Bloom, Laurence Chan, Sanjay Kulkarni, Steven Tomlanovich

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the care of kidney transplant recipients (KTRs), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) organized a working group of transplant nephrologists and surgeons to review these guidelines and comment on their relevance and applicability for US KTRs. The following commentaries on the KDIGO guidelines represent the consensus of our work group. The KDIGO transplant guidelines concentrated on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression, in which decisions in the United States are largely made by transplant centers and are dependent in part on the specific patient population served. Most, but not all, KDIGO guidelines are relevant to US patients. However, implementation of many may remain a major challenge because of issues of limitation in resources needed to assist in the tasks of educating, counseling, and implementing and maintaining lifestyle changes. Although very few of the guidelines are based on evidence that is strong enough to justify their being used as the basis of policy or performance measures, they offer an excellent road map to navigate the complex care of KTRs.

Original languageEnglish (US)
Pages (from-to)189-218
Number of pages30
JournalAmerican Journal of Kidney Diseases
Volume56
Issue number2
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Kidney Diseases
Practice Guidelines
Kidney
Guidelines
Transplants
Immunosuppression
Cardiovascular Infections
Transplant Recipients
Population
Life Style
Counseling
Consensus
Neoplasms

Keywords

  • calcineurin inhibitor (CNI)
  • inhibitor of mammalian target of rapamycin (mTOR inhibitor)
  • KDIGO
  • KDOQI
  • Kidney transplant recipients (KTRs)
  • mycophenolate compound (MPA compound)

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. / Bia, Margaret; Adey, Deborah B.; Bloom, Roy D.; Chan, Laurence; Kulkarni, Sanjay; Tomlanovich, Steven.

In: American Journal of Kidney Diseases, Vol. 56, No. 2, 2010, p. 189-218.

Research output: Contribution to journalArticle

Bia, Margaret ; Adey, Deborah B. ; Bloom, Roy D. ; Chan, Laurence ; Kulkarni, Sanjay ; Tomlanovich, Steven. / KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. In: American Journal of Kidney Diseases. 2010 ; Vol. 56, No. 2. pp. 189-218.
@article{9b6250357e4b48349a23d25efba0087b,
title = "KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients",
abstract = "In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the care of kidney transplant recipients (KTRs), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) organized a working group of transplant nephrologists and surgeons to review these guidelines and comment on their relevance and applicability for US KTRs. The following commentaries on the KDIGO guidelines represent the consensus of our work group. The KDIGO transplant guidelines concentrated on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression, in which decisions in the United States are largely made by transplant centers and are dependent in part on the specific patient population served. Most, but not all, KDIGO guidelines are relevant to US patients. However, implementation of many may remain a major challenge because of issues of limitation in resources needed to assist in the tasks of educating, counseling, and implementing and maintaining lifestyle changes. Although very few of the guidelines are based on evidence that is strong enough to justify their being used as the basis of policy or performance measures, they offer an excellent road map to navigate the complex care of KTRs.",
keywords = "calcineurin inhibitor (CNI), inhibitor of mammalian target of rapamycin (mTOR inhibitor), KDIGO, KDOQI, Kidney transplant recipients (KTRs), mycophenolate compound (MPA compound)",
author = "Margaret Bia and Adey, {Deborah B.} and Bloom, {Roy D.} and Laurence Chan and Sanjay Kulkarni and Steven Tomlanovich",
year = "2010",
doi = "10.1053/j.ajkd.2010.04.010",
language = "English (US)",
volume = "56",
pages = "189--218",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients

AU - Bia, Margaret

AU - Adey, Deborah B.

AU - Bloom, Roy D.

AU - Chan, Laurence

AU - Kulkarni, Sanjay

AU - Tomlanovich, Steven

PY - 2010

Y1 - 2010

N2 - In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the care of kidney transplant recipients (KTRs), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) organized a working group of transplant nephrologists and surgeons to review these guidelines and comment on their relevance and applicability for US KTRs. The following commentaries on the KDIGO guidelines represent the consensus of our work group. The KDIGO transplant guidelines concentrated on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression, in which decisions in the United States are largely made by transplant centers and are dependent in part on the specific patient population served. Most, but not all, KDIGO guidelines are relevant to US patients. However, implementation of many may remain a major challenge because of issues of limitation in resources needed to assist in the tasks of educating, counseling, and implementing and maintaining lifestyle changes. Although very few of the guidelines are based on evidence that is strong enough to justify their being used as the basis of policy or performance measures, they offer an excellent road map to navigate the complex care of KTRs.

AB - In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the care of kidney transplant recipients (KTRs), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) organized a working group of transplant nephrologists and surgeons to review these guidelines and comment on their relevance and applicability for US KTRs. The following commentaries on the KDIGO guidelines represent the consensus of our work group. The KDIGO transplant guidelines concentrated on aspects of transplant care most important to this population in the posttransplant period, such as immunosuppression, infection, malignancy, and cardiovascular care. Our KDOQI work group concurred with many of the KDIGO recommendations except in some important areas related to immunosuppression, in which decisions in the United States are largely made by transplant centers and are dependent in part on the specific patient population served. Most, but not all, KDIGO guidelines are relevant to US patients. However, implementation of many may remain a major challenge because of issues of limitation in resources needed to assist in the tasks of educating, counseling, and implementing and maintaining lifestyle changes. Although very few of the guidelines are based on evidence that is strong enough to justify their being used as the basis of policy or performance measures, they offer an excellent road map to navigate the complex care of KTRs.

KW - calcineurin inhibitor (CNI)

KW - inhibitor of mammalian target of rapamycin (mTOR inhibitor)

KW - KDIGO

KW - KDOQI

KW - Kidney transplant recipients (KTRs)

KW - mycophenolate compound (MPA compound)

UR - http://www.scopus.com/inward/record.url?scp=77955854680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955854680&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2010.04.010

DO - 10.1053/j.ajkd.2010.04.010

M3 - Article

C2 - 20598411

AN - SCOPUS:77955854680

VL - 56

SP - 189

EP - 218

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -